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A  6-months  rodent  toxicology  and pharmacokinetic  (PK)  study  was  performed  to  provide  supportive
safety  data  for  long-term  use  of  intravenous  ceftriaxone  in  a clinical  trial  in  patients  with  amyotrophic
lateral  sclerosis  (ALS).  Ceftriaxone  was  administered  by subcutaneous  injection  at up to  2 g/kg/day  to
Sprague-Dawley  Crl:CD  (SD)  rats.  Ceftriaxone  was  found  to be  safe  and  well  tolerated.  Speciﬁcally,  no
signiﬁcant  differences  in  body  weight  and  food  consumption  were  observed  between  the  treatment  and
control groups.  With  the  exception  of  in  red  cell  parameters  decrease,  there  were  no  ceftriaxone-related
changes  in  hematology,  coagulation,  clinical  chemistry  and  urinalysis  parameters.
Injection  site  trauma  and  associated  reversible  anemia,  likely  due to chronic  blood  loss  at  the  injec-
tion  site,  were  all  attributable  to subcutaneous  route  of administration.  Cecum  dilatation  and  some  skin
changes were  reversible  after  recovery  period,  while  bile  duct  dilatation,  observed  only  in  a few  animals,
persisted.  Changes  in the non-glandular  stomach  do not  have  a human  correlate.  The  no-observed-
adverse-effect  dose  level  (NOAEL)  was  0.5  g/kg/day  ceftriaxone  in  both  sexes.reclinical study Ceftriaxone  showed  rapid  absorption  with  half-life  values  ranging  between  1  and  1.5 h. Addition-
ally,  there  was  no evidence  of accumulation  and  a virtually  complete  elimination  by 16 h after  the  last
dose.  Overall  there  were  no  toxicologically  meaningful  drug-related  animal  ﬁndings  associated  with  the
long-term administration  (6 months)  of  ceftriaxone.  These  results  support  safety  of  long-term  use  of
ceftriaxone  in  human  clinical  trials.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Ceftriaxone is a bactericidal 3rd generation cephalosporin that
nhibits bacterial cell wall mucopeptide synthesis [3]. This beta-
actam antibiotic is approved by the federal drug administration
FDA) for intramuscular or intravenous (IV) delivery at maximum
oses of 2–4 g daily [1] for up to 4–6 weeks [2].
ALS is a neurodegenerative disease characterized by progres-
ive degeneration of motor neurons leading to progressive muscle
aralysis and death within 3–5 years from onset [24], with
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riluzole as the only one FDA-approved treatment [12,19,7]. A large
in-vitro drug screen using multiple models identiﬁed ceftriaxone as
a promising candidate therapy for ALS [13,26]. Subsequent studies
demonstrated that ceftriaxone up-regulates the excitatory amino
acid transporter 2 (EAAT2; mouse-analog GLT-1) transporter [22],
potentially reducing glutamate excitotoxicity. Administration of
ceftriaxone also prolonged survival in a mouse model of ALS [22].
In addition, ceftriaxone has neuroprotective effects in models of
spinal muscular atrophy [20], Huntington’s disease [18], multiple
sclerosis [17] and ischemia [8,15,23]. Based on the promising pre-
clinical data in ALS, a large randomized, placebo- controlled, phase
I–III adaptive design human trial of IV ceftriaxone for the treatment
of ALS was conducted [4,10,28]. In order to support the safety of a
long-term (up to 52 weeks) use of IV ceftriaxone in clinical trials in
ALS patients, further to a 14-day preliminary rodent study (unpub-
lished data), a 6-months chronic toxicological and pharmacokinetic
study in rodents was  designed and executed.
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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. Material and methods
.1. Overall design
A 6-months toxicology and pharmacokinetic (PK) study to
valuate the long term safety of ceftriaxone was performed follow-
ng established international guidelines for evaluating medicinal
roducts [14,9] by Charles River Laboratories Preclinical Services
Spencerville, OH and Worcester, MA). The study was  approved
y the Institutional Animal Care and Use Committee (IACUC). To
uide design and dose selection, a preliminary toxicology and PK
4-day study of daily subcutaneous (SC) ceftriaxone administra-
ion was conducted in rodents (unpublished data). The 6-months
dministration was followed by 1-month recovery period to allow
valuation of reversibility of potential toxicological ﬁndings.
.2. Dosage and administration
Dose levels tested in this study included: 0.25, 0.5, 1 g/kg/day
nd 1 g/kg BID, given approximately 8 h apart (Table 1). These
ere selected based on the toxicity and TK data from a previ-
us 14-day study in rats using the same formulation and route of
njection (unpublished data). The dose of 1 g/kg administered sub-
utaneously twice daily (BID) to rats was considered to produce
eftriaxone exposure comparable to or exceeding that observed in
atients after intravenous injection at the approved clinical ther-
py in human. Therefore, to achieve maximum ceftriaxone systemic
xposure compatible with reasonable survival, the dose of 1 g/kg SC
ID was chosen as the highest dose level for this 6-months study.
Subcutaneous dosing was used because other routes of adminis-
ration were considered problematic for long-term administration
n rodents. IV administration in rats is poorly tolerated, causing
ail necrosis and infection. Intraperitoneal (IP) administration was
lso thought to carry a risk of infection. The SC injection sites were
otated for each dose into four separate quadrants (left scapular,
ight scapular, right mid-dorsal thoracic, and left mid-dorsal tho-
acic).
.3. Test material and control substance
Ceftriaxone for injection was provided in the form of a white
owder by Baxter ACC. Ceftriaxone was mixed with sterile water
nd stored refrigerated in amber glass bottles for up to a week. The
ontrol material was sterile water.
.4. Animals
Sprague-Dawley rats Crl:CD (SD) were provided by Charles River
aboratories Inc. and used in all arms and phases of the studies. Ani-
als were housed individually in suspended stainless steel cages
n a controlled environment (temperature: 22 ± 4 Celsius; humid-
ty 50 ± 20%; light cycle: 12-h light/12-h dark cycle; air changes:
0 or more per hour with 100% fresh air), provided free access to
how and water. They were acclimated to the controlled laboratory
nvironment for 6 days prior to dosing, and weighted and exam-
ned before randomization. A total of 228 male and 228 female rats
articipated in the study. Animals were approximately 8 weeks of
ge at the time of randomization, with body weights ranging from
38 to 274 g for males and 171 to 200 g for females.
.5. Study groups and randomizationAnimals were divided into two main arms: toxicology and phar-
acokinetic (PK) groups (Table 1).
The toxicology arm included 120 male and 120 female animals
ivided into Groups 1–5 and receiving placebo (Group 1) or studyrts 2 (2015) 1396–1403 1397
drug at one of four dosage levels (Groups 2–5) (Table 1). Animals
underwent intermittent observations, and ultimately were evalu-
ated by necropsy.
The PK arm included 84 male and 84 female rats randomized
to placebo or test material. These animals were divided into sub-
groups and blood and urine samples for PK analysis were collected
according to the sample collection schedule (Supplementary Tables
1 and 2).
2.6. Clinical observations and examination schedule
2.6.1. Animal observation
General health/mortality and moribundity checks were per-
formed twice daily. Detailed clinical observations including weight
were performed prior to treatment, weekly and prior to euthana-
sia. Cage-side observations were also performed following dose
administration and daily during the recovery period. Food con-
sumption measurements were recorded weekly. Ophthalmology
examinations were performed by a board-certiﬁed veterinary oph-
thalmologist prior to randomization, during week 26, and prior to
necropsy.
2.6.2. Blood and urine sample collection procedures
Blood and urine samples were collected on the day of necropsy
for all animals and on day 90 and 177 from 10 animals/sex/group
that were ultimately sacriﬁced on day 211. Animals were fasted
overnight prior to sample collections, but had ad libitum access
to water. Blood samples for hematology, coagulation, and chem-
istry were obtained via the orbital plexus while the animals were
under light isoﬂurane anesthesia. Blood sampling for ceftriaxone
concentration was  obtained through jugular vein puncture under
isoﬂurane anesthesia per sample collection schedule (Supplemen-
tary Tables 1 and 2). Urine samples for urinalysis were collected by
cage pan drainage overnight.
2.6.3. Necropsy and histopathology
All animals surviving to the planned necropsy day were euth-
anized by exsanguination while under deep anesthesia induced
with carbon dioxide inhalation. Organs were weighted and selected
organs were collected and preserved. Slides from tissues of inter-
est were examined microscopically by a board-certiﬁed veterinary
pathologist.
2.7. Pharmacokinetics procedures
A volume of approximately 0.0250 mL  was collected into
tubes containing K3EDTA as anticoagulant. Samples were analyzed
according to a method including sample extraction by protein
precipitation and ﬁnal extract analyses by liquid chromatography
(LC)/mass spectroscopy (MS). The method was  validated for anal-
ysis of ceftriaxone in 0.0250 mL  sample volumes of K3EDTA rat
plasma over a concentration range of 1.00–500 g/mL.
2.8. Statistical analysis
Inferential statistical analyses were performed for the toxicol-
ogy and recovery phase animals, analyzing body weight, change in
body weight, food consumption, hematology, coagulation, clinical
chemistry, urinalysis, and organ weights. The data were initially
analyzed for homogeneity of variance using Levene’s test (p < 0.01)
followed by the Shapiro–Wilk test for normality (p < 0.05). If
both assumptions were fulﬁlled, a single-factor (animal grouping)
ANOVA was  applied, otherwise the Kruskal–Wallis ANOVA was
applied. If the ANOVA was  signiﬁcant at p < 0.05, Dunnett’s test
(parametric ANOVA) or Dunn’s test (K–W ANOVA) was  used to
compare the control group to each test article-treated group at
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Table 1
Dosage level groups.
Group no. Toxicology arm
(male/female)
PKa arm
(male/female)
Test material Dose and
frequency days
0–49 (g/kg)
Adjusted
frequency days
50–182 (g/kg)
Recovery days
(no drug
delivered)
Day of
necropsy
1 20/20 6/6 Sterile water 0 bidb sidc – 182–4
1  Recovery 10/10 – Sterile water 0 bid sid 182–211 211
2  20/20 18/18 Ceftriaxone 0.25 sid No adjustment – 182–4
3  20/20 18/18 Ceftriaxone 0.5 sid No adjustment – 182–4
4  20/20 18/18 Ceftriaxone 1 sid No adjustment – 182–4
4  Recovery 10/10 – Ceftriaxone 1 bid sid 182–211 211
5  15/15 24/24 Ceftriaxone 1 bid – – 50
5  Recovery 5/5 – Ceftriaxone 1 bid – 50–78 78
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ca PK: pharmacokinetics.
b bid: twice a day, approximately 8 h apart.
c sid: once per day.
he 0.05, 0.01, and 0.001 levels of signiﬁcance. Mean ceftriaxone
oncentration-time data for males and females separately were
ubjected to non-compartmental PK analysis using WinNolin 1.5
ith nominal sampling times.
. Results
.1. Mortality
Mortality was limited and was not deemed related to ceftriax-
ne. Five animals died by accidental death prior to 3 weeks. Four
f these animals died on day 1 in the pharmacokinetic arm of the
tudy. The ﬁfth belonged to the toxicology arm and was  replaced
n day 15. One Group 1 (control group) male was found dead on
tudy day 177. The cause of death was considered to be severe
nﬂammation of the kidney and lower urinary tract.
.2. Clinical observations
No overt clinical signs of toxicity were noted in males and
emales in the control or treated groups. An increased incidence
f swelling was observed during the treatment period at the injec-
ion site of Groups 1, 4 and 5 animals, more frequently in males. The
rritation at the injection site was particularly relevant in Group 5,
herefore, BID dosing was discontinued after Day 49. On day 50,
5 animals per sex from Group 5 were terminated. Another ﬁve
nimals per sex from Group 5 were allowed a 4-week recovery
eriod and necropsied on Day 78. The remaining 10 animals per
ex from Group 5 continued receiving study drug at a reduced fre-
uency (once daily 1 g/kg/day) for a minimum of 182 days, followed
y a 4-week recovery period and necropsy on Day 211 (Table 1).
o remarkable clinical signs were observed during the recovery
eriod, including swelling at the injection site that had almost com-
letely resolved during this time.
.3. Body weight and food consumption
There were no toxicologically meaningful differences in mean
ody weights or body weight gains for animals in the treated
roups compared to controls (Fig. 1). Mean body weights of males
n Groups 4 and 5 were statistically lower than controls during
he treatment period (Fig. 1a). However, the differences were not
onsidered toxicologically meaningful since the Group 4 and 5
ean body weights remained within approximately 10% of controls
hroughout the treatment period. Mean body weights of females in
he treated groups were comparable or slightly higher than controls
hroughout the study (Fig. 1b).
There were no toxicologically meaningful differences in mean
ood consumption for animals in the treated groups compared to
ontrols. The few statistically signiﬁcant differences in mean foodconsumption were not considered toxicologically meaningful since
they did not follow a consistent pattern and, often, the mean val-
ues were higher, rather than lower, in treated groups compared to
controls.
3.4. Clinical chemistry, urinalysis and hematology
Several clinical chemistry parameters in the treated groups were
found signiﬁcantly different from the control group. However, all
the differences were considered slight and the absolute values
remained within the limits of normal for this species. The differ-
ences found in the urinalysis were not considered toxicologically
meaningful since they did not follow a consistent pattern or dose
response.
Hematology analysis showed decreased red cell parameters
(erythrocyte count, hemoglobin, hematocrit, mean corpuscular
hemoglobin concentration (MCHC)) and increased reticulocyte
count and ﬁbrinogen in Group 5 animals terminated early (Day 50)
(Supplementary Table 3). Similar hematology parameters changes
were also observed in Group 4 and Group 4 recovery on days 90
and 177. These ﬁndings were reversible in Group 5 recovery ani-
mals euthanized on Day 78 (Supplementary Table 3). In addition,
changes in red cell parameters in the Group 4 female recovery group
as well as reticulocytes counts (Supplementary Table 4) and ﬁb-
rinogen normalized on day 211. These hematologic ﬁndings were
consistent with iron deﬁciency anemia due to slow blood loss,
which was attributed to irritation at the injection site.
3.5. Gross necropsy
Gross necropsy ﬁndings included enlarged cecum in treated ani-
mals at scheduled euthanasia at the end of the treatment period
and thickened and discolored injection site in animals belonging to
both the control and treated groups at the end of the treatment and
recovery periods (Supplementary Table 5).
The enlarged ceca appeared dose-related as did the discolored
skin injection sites. Skin thickening was  observed in all groups,
including the control group. Virtually all animals in Group 5 had
an enlarged cecum on day 50 as well as thickened and discolored
skin at the injection sites. The enlarged ceca and thickened skin
had almost completely resolved at the end of the recovery period
for this group (day 78).
At the end of the recovery period on day 211, cecum size
appeared normal, while, thickened and discolored skin remained a
frequent ﬁnding.
In the stomach, discoloration, foci, or thickening were observed
in the non-glandular stomach of some Group 4 animals (Sup-
plementary Table 5). The discoloration and foci correlated
microscopically with hyperplasia, and occasionally, with degen-
eration or ulcer of the stratiﬁed squamous epithelium, while
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Fig. 1. Mean body weights. (a) Male group mean bo
hickening correlated either with epithelial hyperplasia or edema
f the wall of the non-glandular stomach.
Discoloration, foci or thickening were each found in the
landular stomach of one Group 4 animal in association with
on-glandular stomach changes in two out of the three animals
onsidered. In these rare cases, glandular stomach discoloration
nd thickening correlated microscopically with edema of the stom-
ch wall, while black foci correlated with erosion. At the recovery
acriﬁces, gross ﬁndings related to ceftriaxone administration were
bserved at the injection site, in the cecum, and common bile duct.
ross dilation of the common bile duct with spherical contents was
bserved in a few treated males. The dilation was  conﬁrmed micro-
copically. No correlate to the spherical content was  observed but
hese were presumably choleliths which were lost during tissue
rocessing.
.6. Organ weights
Absolute cecum weights and cecum weights relative to body
eight were signiﬁcantly increased for males in Groups 2–4 com-
ared to controls at study termination (days 183–185) (Fig. 2).
Absolute adrenal weights and adrenal weights relative to bodyeight were signiﬁcantly increased for males in Group 4 com-
ared to controls at study termination (days 183–185) (Fig. 2). The
ncrease in adrenal weights in Group 4 males may  have been related
o the stress of injections, which proved to be highly irritating.ights (g), (b) female group mean body weights (g).
3.7. Histopathology
Histopathologic effects related to ceftriaxone administration
were observed at the injection site, and in the cecum, common bile
duct, and stomach (glandular and non-glandular) (Table 2).
Findings at the injection site at the terminal necropsy included
ﬁbrosis, hemorrhage, and pigmentation. Fibrosis occurred with
similar incidence across groups of control and treated animals.
The average severity of ﬁbrosis was also similar across control and
treated groups of males, while in females it was greater in treated
groups than in control and was  greatest in the two  highest dose
female groups (Groups 4 and 5).
Hemorrhage occurred commonly across all groups but the
average severity was greater in treated groups than in controls.
Incidences and average severities were somewhat less in Group
5 high-dose animals than in other treated groups, presumably
because these animals were sacriﬁced earlier than animals from
the other treated groups and therefore received fewer injections.
Pigmentation was  observed frequently in Groups 3–5 animals
with an average severity greater in Groups 3 and 4 animals
compared to Group 5, presumably because Group 5 animals
were sacriﬁced earlier than others. Microscopically, pigmentation
consisted of variable numbers of macrophages, ﬁlled with dark
brown/black granular material, scattered within the dermal ﬁbrous
tissue. In some cases, as in the control female, the pigment may
have been hemosiderin resulting from hemorrhage. In most cases,
however, the nature of the pigment was uncertain.
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Table 2
Summary of relevant histopathology at terminal sacriﬁce.
(a) Summary of relevant histopathology in males at terminal sacriﬁce
Organ Lesion Group 1b Group 2 Group 3 Group 4 Group 5
Kidney Nephropathy 9/20 NEa 0/1 5/20 12/15
Minimal 9 5 11
Mild 0 0 1
Bile  duct Hyperplasia 0/20 NE NE 0/20 2/15
Minimal 0 1
Mild 0 1
Dilatation 1/18 0/17 0/20 1/19 1/1
Minimal 0/18 1/19 0/1
Mild 1/18 0/19 0/1
Marked 0/18 0/19 1/1
Cholelithiasis 0/18 0/17 0/20 0/19 1/1
Marked 1/1
Cecum Dilatation 0/20 5/20 8/20 11/20 15/15
Minimal 0 0 5 0
Mild 5 6 6 3
Moderate 0 2 0 12
STomach
non-glandular
Hyperplasia 0/20 1/20 3/20 4/20 0/15
Minimal 1 1 1
Mild  0 2 1
Marked 0 0 2
Edema 0/20 0/20 0/20 3/20 0/15
Moderate 3
Marked 0
Inﬂammation 0/20 0/20 0/20 0/20 0/15
Ulceration 0/20 0/20 0/20 0/20 0/15
Stomach glandular Edema 0/20 0/20 0/20 1/20 0/15
Mild 1
Inﬂammation 0/20 0/20 0/20 1/20 0/15
Minimal 1
Erosion 0/20 0/20 0/20 0/20 0/15
Injection site Fibrosis 20/20 19/20 20/20 20/20 15/15
Minimal 2 7 3 0 0
Mild 5 9 10 7 5
Moderate 8 2 5 9 8
Marked 5 1 2 4 2
Hemorrhage 16/20 19/20 20/20 20/20 15/15
Minimal 12 9 3 4 0
Mild 4 9 7 7 13
Moderate 0 1 7 5 2
Marked 0 0 3 4 0
Pigmentation 0/20 0/20 8/20 18/20 8/15
Minimal 3 2 7
Mild 3 7 1
Moderate 2 6 0
Marked 0 3 0
(b)  Summary of relevant histopathology in females at terminal sacriﬁce
Organ Lesion Group 1b Group 2 Group 3 Group 4 Group 5
Kidney Nephropathy 1/20 NEa 0/2 0/20 3/15
Minimal 1 2
Mild  0 1
Bile  duct Hyperplasia 1/20 NE NE 1/20 0/15
Minimal 1 1
Dilatation 0/17 0/20 0/17 0/20 NE
Cholelithiasis 0/17 0/20 0/17 0/20 NE
CECUM Dilatation 0/20 7/20 9/20 14/20 15/15
Minimal 1 1 3 0
Mild  6 8 6 3
Moderate 0 0 5 12
Stomach non-glandular Hyperplasia 0/20 3/20 3/20 8/20 0
Minimal 2 3 0
Mild 0 0 4
Marked 1 0 4
Edema 0/20 0/20 0/20 1/20 0/15
Moderate 0
Marked 1
Inﬂammation 0/20 0/20 0/20 2/20 0/15
Minimal 1
Mild 1
Ulceration 0/20 0/20 0/20 1/20 0/15
Mild 1
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Table  2 (Continued)
(a) Summary of relevant histopathology in males at terminal sacriﬁce
Organ Lesion Group 1b Group 2 Group 3 Group 4 Group 5
Stomach glandular Edema 0/20 0/20 0/20 1/20 0/15
Mild 1
Inﬂammation 0/20 0/20 0/20 0/20 0/15
Erosion 0/20 0/20 0/20 1/20 0/15
Mild 1
Injection site Fibrosis 19/20 17/20 20/20 20/20 15/15
Minimal 13 13 4 0 1
Mild 5 4 12 4 4
Moderate 1 0 3 8 7
Marked 0 0 1 8 3
Hemorrhage 13/20 19/20 20/20 20/20 14/15
Minimal 11 14 9 1 4
Mild 2 5 8 5 9
Moderate 0 0 2 12 1
Marked 0 0 1 2 00
Pigmentation 1/20 1/20 13/20 19/20 8/15
8
Minimal 1 1 10 4 8
Mild 0 0 3 6 0
Moderate 0 0 0 8 0
Marked 0 0 0 1 0
a NE: not examined.
b Group 1 (0 g/kg/day); Group 2 (0.25 g/kg/day); Group 3 (0.5 g/kg/day); Group 4 (1.0 g/
1.99
3.19 3.12 3.08
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Fig. 2. Statistically signiﬁcant organ weights changes.kg/day); Group 5 (2.0/1.0 g/kg/day).
Cecum dilatation occurred in all treated groups of males and
females with a dose-related incidence and average severity. Grossly
the affected ceca were enlarged up to approximately two times the
normal size. Microscopically dilated ceca appeared only longer and
with thinner mucosa.
Dilatation of the common bile duct was  observed in one con-
trol male, one Group 4 male, and one Group 5 male. The latter also
had cholelithiasis. Microscopically, the dilatation was character-
ized by an increase in the bile duct diameter, from approximately
four times normal in the Group 1 male up to approximately 10
times normal size in the Group 5 male. The ﬁbrous connective tis-
sue wall of the dilated duct was  variably thickened, while the biliary
epithelium was generally hyperplastic.
In the non-glandular stomach, hyperplasia of the stratiﬁed squa-
mous epithelium was observed in animals from Groups 2–4. In
addition, edema of the non-glandular stomach was  found in a few
males and in one female from Group 4; inﬂammation in two Group
4 females; and ulceration in one Group 4 female. In the glandular
stomach, edema was  observed in one Group 4 male with epithe-
lial degeneration of the non-glandular stomach, and in one Group
4 female with epithelial hyperplasia of the non-glandular stomach.
Moreover, in the glandular stomach, inﬂammation was found in
one Group 4 male and mucosal erosion was  seen in one Group 4
female.
Nephropathy occurred with somewhat higher incidence in
Group 5 males as compared with Group 1 males. Nephropathy is a
common spontaneous change in male SD rats as they age [5], thus
the higher incidence in the Group 5 males may  simply represent
a random variation in the normal background ﬁnding and it was
deemed not to be toxicologically meaningful.
Based on the evaluation of the study results, the no-observed-
adverse-effect dose level is considered to be 0.5 g/kg/day.
3.8. Pharmacokinetic
Pharmacokinetic ﬁndings are summarized in Table 3. Ceftri-
axone was rapidly absorbed after subcutaneous injection; the
maximum plasma level was reached in 1 h. Ceftriaxone was also
very rapidly cleared, with a plasma half-life ranging between 1 and
1.5 h. Values for Cmax and AUClast were found similar for each dosage
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Table 3
Summary of pharmacokinetics measures at day 182.
Group (N = 6 M and 6F) Dosage (g/kg/dose) Sex Cmax (mean ± SD) (g/mL) tmax (h) tlast (h) AUClast (g h/mL) AUC (g h/mL) t1/2 (h)
2 0.25 sidb M 262 ± 38.4 1 8 831 861 1.6
F  205 ± 142 2 8 906 NEa NEa
3 0.5 sid M 381 ± 53.6 1 8 1070 1090 1.2
F  404 ± 26.5 1 8 1160 1190 1.3
4 1.0  sid M 607 ± 144 1 8 1570 1610 1.5
F  669 ± 119 1 8 1690 1740 1.5
mean
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oa NE: not estimated, due to insufﬁcient characterization of the terminal phase of 
b sid: once daily.
evel at each time point (days 1, 84, and 182) for Groups 1–4. No
ccumulation was observed.
Average urinary recovery was approximately 32% of the dose.
he tmax was 2 h, with virtually all ceftriaxone excreted by 16 h
Supplementary Table 6).
. Discussion
The study described was aimed at assessing the safety of cef-
riaxone administered subcutaneously in rats at dosages up to
 g/kg/day with a duration of 6 months in order to support a 52
eeks clinical trial of ceftriaxone for the treatment of ALS [4,10,28]
In general, ceftriaxone was found to be safe and well toler-
ted. No toxicologically meaningful changes in body weight, food
onsumption and ocular ﬁndings between the treated and con-
rol groups were observed. In addition, apart from the decrease in
ed cell parameters, there were no ceftriaxone-related changes in
ematology, coagulation, clinical chemistry and urinalysis param-
ters.
Injection site trauma and the associated reversible anemia most
ikely due to chronic blood loss at the injection site, were all
ttributable to subcutaneous route of administration. This route
f administration was chosen in an attempt to avoid the challenges
nherent to chronic intra-peritoneal or intravenous drug adminis-
ration in rats. These ﬁndings are not relevant for human use of
eftriaxone, as it is administered intravenously.
Cecal enlargement in ceftriaxone-treated animals was a
eversible ﬁnding without any corresponding histolpathological
hanges and was observed also in previous toxicological studies
ith ceftriaxone [25]. To our knowledge, an adult human correlate
as never been reported.
Nephropathy was observed in both the control and treatment
roups. Since nephropathy is a common spontaneous complica-
ion observed in male Sprague–Dawley rats as they age [5] and
as also present in control males, its toxicological relevance was
nclear. However, as renal complications associated with ceftriax-
ne are known in humans, in order to avoid renal adverse events,
atients enrolled in the clinical trial receiving chronic ceftriaxone
ad regular urinalysis and blood tests for electrolytes, creatinine
nd BUN monitoring. If there was concern for renal dysfunction,
nd if serum creatinine rose of 25% or more from the screening visit
evel, the patients’ drug administration was interrupted to allow
urther evaluation under the guidance of a nephrologist.
Previous preclinical studies showed that administration of cef-
riaxone in dogs receiving 100 mg/kg/day for 4 weeks and in
aboons receiving ≥335 mg/kg/day for six months was associated
ith calcium salt of ceftriaxone concretions in the gallbladder bile
1]. In the present study, bile duct dilatation was observed only in a
ew animals across all the study groups and cholelithiasis was con-
rmed only in one animal treated at the highest dose, while loss
f dilated bile ducts content during the tissue processing cannot
e excluded. Humans are known to develop pseudo-cholelithiasis,
r sludging of the bile in the gallbladder and/or common bile duct, concentration-time curve.
when treated with ceftriaxone for only three or ten days [6,21]. For
this reason, in the trial of ceftriaxone for the treatment of ALS [4,10],
liver function tests have been regularly assessed. Participants with
symptoms underwent ultrasound to identify the development of
bile sludge or stones, and ceftriaxone was  held for participants with
symptoms and/or signs of cholelithiasis. Since ursodeoxycholic acid
might prevent or reduce the occurrence of pseudocholelithiasis
[27,11] and signiﬁcantly shortened event duration of biliary sludg-
ing and cholelithiasis in the ﬁrst phases of the clinical trial [4], it
was administered in all the patients treated with ceftriaxone in the
Phase III of the trial to prevent biliary obstruction [10].
Finally, changes in the non-glandular stomach wall were
observed. The non-glandular stomach is a common site of irritation
in the rat and similar ﬁndings have been described by other authors
[16]. Because humans lack the rat’s non-glandular stomach, there
is no human correlate to these changes. Only a small number of ani-
mals developed limited changes in the glandular stomach, which
are unlikely to have any clinically signiﬁcance in humans.
Overall there were no toxicologically meaningful drug-related
animal ﬁndings associated with the long-term administration (6
months) of ceftriaxone. This study can then support the clinical
long-term use of ceftriaxone in any future trials for indications that
require chronic treatments and in particular has provided the pre-
clinical toxicological support for the human trial of ceftriaxone for
ALS [4,10] .
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